Pathogenesis, treatment effects, and resistance dynamics in chronic myeloid leukemia--insights from mathematical model analyses (Q36895345)

16 August 2017

1 reference

title

Pathogenesis, treatment effects, and resistance dynamics in chronic myeloid leukemia--insights from mathematical model analyses (English)

1 reference

16 August 2017

chronic myeloid leukemia

0 references

1 reference

Ingo Roeder

1

1 reference

PubMed ID

17661001

16 August 2017

Ingmar Glauche

series ordinal

2

1 reference

16 August 2017

28 July 2007

1 reference

Journal of Molecular Medicine

16 August 2017

1 reference

16 August 2017

86

1 reference

16 August 2017

1

1 reference

16 August 2017

17-27

1 reference

https://scigraph.springernature.com/pub.10.1007/s00109-007-0241-y

16 August 2017

0 references

cites work

New insights into the pathophysiology of chronic myeloid leukemia and imatinib resistance

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS00109-007-0241-Y

BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571.

21 January 2018

1 reference

12 December 2020

Phosphatidylinositol-3 kinase activity is regulated by BCR/ABL and is required for the growth of Philadelphia chromosome-positive cells

1 reference

12 December 2020

Intermittent exposure of primitive quiescent chronic myeloid leukemia cells to granulocyte-colony stimulating factor in vitro promotes their elimination by imatinib mesylate

1 reference

12 December 2020

Nonproliferating CML CD34+ progenitors are resistant to apoptosis induced by a wide range of proapoptotic stimuli

1 reference

12 December 2020

Molecular heterogeneity in complete cytogenetic responders after interferon-alpha therapy for chronic myelogenous leukemia: low levels of minimal residual disease are associated with continuing remission. German CML Study Group and the UK MRC CML St

1 reference

12 December 2020

High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients: correlation with clonal cytogenetic evolution but not response to therapy

1 reference

12 December 2020

Mechanisms of resistance to imatinib in CML patients: a paradigm for the advantages and pitfalls of molecularly targeted therapy

1 reference

12 December 2020

Constitutive activation of JAKs and STATs in BCR-Abl-expressing cell lines and peripheral blood cells derived from leukemic patients

1 reference

12 December 2020

The molecular biology of chronic myeloid leukemia.

1 reference

12 December 2020

BCR-ABL down-regulates the DNA repair protein DNA-PKcs

1 reference

12 December 2020

Imatinib mesylate selectively influences the cellular metabolism of cytarabine in BCR/ABL negative leukemia cell lines and normal CD34+ progenitor cells

1 reference

12 December 2020

Spontaneous reversion from blast to chronic phase after withdrawal of imatinib mesylate in a patient with chronic myelogenous leukemia

1 reference

12 December 2020

Detection and quantification of residual disease in chronic myelogenous leukemia.

1 reference

12 December 2020

Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy

1 reference

12 December 2020

Monitoring minimal residual disease in BCR-ABL-positive chronic myeloid leukemia in the imatinib era.

1 reference

12 December 2020

Reduced focal adhesion kinase and paxillin phosphorylation in BCR-ABL-transfected cells

1 reference

12 December 2020

Granulocyte--colony-stimulating factor (Filgrastim) may overcome imatinib-induced neutropenia in patients with chronic-phase myelogenous leukemia

1 reference

12 December 2020

Drug resistance in cancer: principles of emergence and prevention

1 reference

12 December 2020

Structural mechanism for STI-571 inhibition of abelson tyrosine kinase

1 reference

12 December 2020

P210 and P190(BCR/ABL) induce the tyrosine phosphorylation and DNA binding activity of multiple specific STAT family members

1 reference

12 December 2020

Integrin-mediated regulation of hematopoiesis: do BCR/ABL-induced defects in integrin function underlie the abnormal circulation and proliferation of CML progenitors?

1 reference

12 December 2020

The development of imatinib as a therapeutic agent for chronic myeloid leukemia

1 reference

12 December 2020

BCR/ABL regulates mammalian RecA homologs, resulting in drug resistance

1 reference

12 December 2020

Quiescence, cycling, and turnover in the primitive hematopoietic stem cell compartment.

1 reference

12 December 2020

Evolutionary dynamics of escape from biomedical intervention.

1 reference

12 December 2020

Growth factor stimulation reduces residual quiescent chronic myelogenous leukemia progenitors remaining after imatinib treatment

1 reference

12 December 2020

Dynamic modeling of imatinib-treated chronic myeloid leukemia: functional insights and clinical implications.

1 reference

12 December 2020

Imatinib mesylate in combination with other chemotherapeutic agents for chronic myelogenous leukemia

1 reference

12 December 2020

Successful therapy must eradicate cancer stem cells.

1 reference

12 December 2020

Selecting and deselecting imatinib-resistant clones: observations made by longitudinal, quantitative monitoring of mutated BCR-ABL.

1 reference

12 December 2020

Induction of apoptosis in chronic myelogenous leukemia cells through nuclear entrapment of BCR-ABL tyrosine kinase.

1 reference

12 December 2020

Dynamics of chronic myeloid leukaemia.

1 reference

12 December 2020

Towards predictive models of stem cell fate.

1 reference

12 December 2020

Long-term clinical and molecular follow-up of large animals receiving retrovirally transduced stem and progenitor cells: no progression to clonal hematopoiesis or leukemia

1 reference

12 December 2020

Imatinib mesylate in the treatment of chronic myelogenous leukemia

1 reference

12 December 2020

Emergence and prevention of resistance against small molecule inhibitors

1 reference

12 December 2020

Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL.

1 reference

12 December 2020

Chronic myelogenous leukemia.

1 reference

12 December 2020

In vivo proliferation and cell cycle kinetics of long-term self-renewing hematopoietic stem cells

1 reference

12 December 2020

Denaturing-HPLC-based assay for detection of ABL mutations in chronic myeloid leukemia patients resistant to Imatinib

1 reference

12 December 2020

Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment.

1 reference

12 December 2020

Role of alpha1 acid glycoprotein in the in vivo resistance of human BCR-ABL(+) leukemic cells to the abl inhibitor STI571

1 reference

12 December 2020

The presence of a BCR-ABL mutant allele in CML does not always explain clinical resistance to imatinib

1 reference

12 December 2020

Leukaemia stem cells: hit or miss?

1 reference

12 December 2020

Current CML therapy: progress and dilemma

1 reference

12 December 2020

The kinetics of clonal dominance in myeloproliferative disorders

1 reference

12 December 2020

Imatinib mesylate (STI571) inhibits growth of primitive malignant progenitors in chronic myelogenous leukemia through reversal of abnormally increased proliferation

1 reference

12 December 2020

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

1 reference

12 December 2020

Autocrine production and action of IL-3 and granulocyte colony-stimulating factor in chronic myeloid leukemia.

1 reference

12 December 2020

Resistance to tumor specific therapy with imatinib by clonal selection of mutated cells

1 reference

12 December 2020

The tyrosine kinase inhibitor CGP 57148 (ST1 571) induces apoptosis in BCR-ABL-positive cells by down-regulating BCL-X

1 reference

12 December 2020

Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia

1 reference

12 December 2020

Conceptual models to understand tissue stem cell organization

1 reference

12 December 2020

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

1 reference

12 December 2020

Primitive quiescent leukemic cells from patients with chronic myeloid leukemia spontaneously initiate factor-independent growth in vitro in association with up-regulation of expression of interleukin-3

1 reference

12 December 2020

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells

1 reference

12 December 2020

Dynamics of cancer progression

1 reference

12 December 2020

Targeted CML therapy: controlling drug resistance, seeking cure

1 reference

12 December 2020

Quantitative stem cell biology: computational studies in the hematopoietic system

1 reference

12 December 2020

Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro

1 reference

12 December 2020

Survival advantage from imatinib compared with the combination interferon- plus cytarabine in chronic-phase chronic myelogenous leukemia: historical comparison between two phase 3 trials

1 reference

12 December 2020

10.1007/S00109-007-0241-Y

Identifiers

DOI

1 reference

16 August 2017

1 reference

PubMed ID

17661001